DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma

Interventions: Drug: Oncaspar
Drug: SC-PEG

First Posted Date: 2012-04-10

Last Posted Date: 2024-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 240

Registration Number: NCT01574274

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

and more 5 locations

XL-184+Abiraterone in Post-Chemo CRPC

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cabozantinib
Drug: Abiraterone

First Posted Date: 2012-04-10

Last Posted Date: 2021-08-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT01574937

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Other: MRI

First Posted Date: 2012-04-02

Last Posted Date: 2016-08-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT01568346

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Faulkner Hospital, Boston, Massachusetts, United States

Ruxolitinib in Patients With Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Ruxolitinib

First Posted Date: 2012-03-26

Last Posted Date: 2017-02-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01562873

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Ganetespib

First Posted Date: 2012-03-22

Last Posted Date: 2024-11-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT01560416

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
New Hampshire Oncology and Hematology, P.A., Concord, New Hampshire, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: STA-9090

First Posted Date: 2012-03-13

Last Posted Date: 2017-04-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01551693

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2012-02-01

Last Posted Date: 2024-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT01523977

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
UCSF, San Francisco, California, United States

and more 5 locations

Study of Vitamin D in Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: FOLFOX + bevacizumab
Dietary Supplement: Vitamin D

First Posted Date: 2012-01-24

Last Posted Date: 2022-04-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 139

Registration Number: NCT01516216

Locations: 🇺🇸
Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States
🇺🇸
Lowell General Hospital, Lowell, Massachusetts, United States
🇺🇸
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States

and more 13 locations

The Preoperative Health & Body Study

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: Exercise
Behavioral: Surgical preparation program

First Posted Date: 2012-01-24

Last Posted Date: 2024-10-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT01516190

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Socialization of Adult Men With Congenital Hemophilia A or B

Completed

Conditions: Hemophilia A
Hemophilia B

First Posted Date: 2012-01-16

Last Posted Date: 2016-08-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT01510418

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy